US equities
|
SPCX
$171.09
▲+0.00%
NVDA
$238.90
▲+0.00%
MU
$1,063.96
▲+0.00%
SDEV
$3.94
▲+0.00%
SNDK
$1,704.16
▲+0.00%
SKHY
$195.02
▲+0.00%
AMD
$631.75
▲+0.00%
TSLA
$378.73
▲+0.00%
SPCX
$171.09
▲+0.00%
NVDA
$238.90
▲+0.00%
MU
$1,063.96
▲+0.00%
SDEV
$3.94
▲+0.00%
SNDK
$1,704.16
▲+0.00%
SKHY
$195.02
▲+0.00%
AMD
$631.75
▲+0.00%
TSLA
$378.73
▲+0.00%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Articles published by ASLAN PHARMACEUTICALS LIMITED
ASLAN Pharmaceuticals Announces it Has Filed for Voluntary Liquidation of Its Sole Operating Subsidiary and is Commencing Steps to Place Itself Into Voluntary Liquidation
July 17, 2024
From
ASLAN PHARMACEUTICALS LIMITED
Via
GlobeNewswire
Tickers
ASLN
ASLAN Pharmaceuticals Announces Receipt of Nasdaq Delisting Determination; Has Determined Not to Appeal
July 15, 2024
From
ASLAN PHARMACEUTICALS LIMITED
Via
GlobeNewswire
Tickers
ASLN
ASLAN Pharmaceuticals Announces Plan to Implement ADS Ratio Change
June 14, 2024
From
ASLAN PHARMACEUTICALS LIMITED
Via
GlobeNewswire
Tickers
ASLN
ASLAN Pharmaceuticals Presents Late-Breaking Translational Data on Eblasakimab in COPD at the American Thoracic Society International Conference
May 21, 2024
From
ASLAN PHARMACEUTICALS LIMITED
Via
GlobeNewswire
Tickers
ASLN
ASLAN Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update
May 09, 2024
From
ASLAN PHARMACEUTICALS LIMITED
Via
GlobeNewswire
Tickers
ASLN
ASLAN Pharmaceuticals to Present Additional Data From Interim Analysis of TREK-DX Phase 2 Study of Eblasakimab in Dupilumab-Experienced Atopic Dermatitis Patients During Virtual KOL Event
May 07, 2024
From
ASLAN PHARMACEUTICALS LIMITED
Via
GlobeNewswire
Tickers
ASLN
ASLAN Pharmaceuticals Announces Expansion of its Collaboration With Zenyaku to Investigate the Biology Underlying Differential Effects of Eblasakimab Compared to Other Biologics
May 02, 2024
From
ASLAN PHARMACEUTICALS LIMITED
Via
GlobeNewswire
Tickers
ASLN
ASLAN Pharmaceuticals to Host KOL Panel Discussion on Treatment Options for Atopic Dermatitis Patients With an Inadequate Response to Dupilumab
April 30, 2024
From
ASLAN PHARMACEUTICALS LIMITED
Via
GlobeNewswire
Tickers
ASLN
ASLAN Pharmaceuticals Announces Late Breaking Abstract on Eblasakimab in COPD Accepted for Presentation at the American Thoracic Society International Conference
April 24, 2024
From
ASLAN PHARMACEUTICALS LIMITED
Via
GlobeNewswire
Tickers
ASLN
ASLAN Pharmaceuticals Announces Positive Interim Results From Phase 2 Study of Eblasakimab in Dupilumab-Experienced Atopic Dermatitis Patients
April 22, 2024
From
ASLAN PHARMACEUTICALS LIMITED
Via
GlobeNewswire
Tickers
ASLN
ASLAN Pharmaceuticals Announces Receipt of Nasdaq Notice
April 19, 2024
From
ASLAN PHARMACEUTICALS LIMITED
Via
GlobeNewswire
Tickers
ASLN
ASLAN Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
April 12, 2024
From
ASLAN PHARMACEUTICALS LIMITED
Via
GlobeNewswire
Tickers
ASLN
Aslan Pharmaceuticals to Present at the 2nd Annual H.C. Wainwright Autoimmune and Inflammatory Disease Virtual Conference: Skin Diseases, Conditions and Disorders
March 27, 2024
From
ASLAN PHARMACEUTICALS LIMITED
Via
GlobeNewswire
Tickers
ASLN
ASLAN Pharmaceuticals Announces $5 Million Registered Direct Offering
March 12, 2024
From
ASLAN PHARMACEUTICALS LIMITED
Via
GlobeNewswire
Tickers
ASLN
ASLAN Pharmaceuticals Provides TREK-DX Study Update and Highlights Potential of Eblasakimab in Dupilumab-Experienced Atopic Dermatitis Patients
March 11, 2024
From
ASLAN PHARMACEUTICALS LIMITED
Via
GlobeNewswire
Tickers
ASLN
ASLAN Pharmaceuticals Announces New Translational Data on Eblasakimab in COPD and Appoints Leading Respiratory Experts as Scientific Advisors
March 06, 2024
From
ASLAN PHARMACEUTICALS LIMITED
Via
GlobeNewswire
Tickers
ASLN
ASLAN Pharmaceuticals Receives Favorable Opinion From the European Patent Office on Composition of Matter Patent Application for Farudodstat
February 29, 2024
From
ASLAN PHARMACEUTICALS LIMITED
Via
GlobeNewswire
Tickers
ASLN
ASLAN Pharmaceuticals Announces Receipt of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement
January 08, 2024
From
ASLAN PHARMACEUTICALS LIMITED
Via
GlobeNewswire
Tickers
ASLN
ASLAN Pharmaceuticals Announces Participation in January Investor Conferences
January 02, 2024
From
ASLAN PHARMACEUTICALS LIMITED
Via
GlobeNewswire
Tickers
ASLN
ASLAN Pharmaceuticals Provides Year-End Update on Its Eblasakimab and Farudodstat Programs
December 12, 2023
From
ASLAN PHARMACEUTICALS LIMITED
Via
GlobeNewswire
Tickers
ASLN
ASLAN Pharmaceuticals to Participate in the 35th Annual Piper Sandler Healthcare Conference
November 20, 2023
From
ASLAN PHARMACEUTICALS LIMITED
Via
GlobeNewswire
Tickers
ASLN
ASLAN Pharmaceuticals Presents New Data on Eblasakimab in Atopic Dermatitis and COPD Translational Models at the 7th Dermatology Drug Development Summit
November 03, 2023
From
ASLAN PHARMACEUTICALS LIMITED
Via
GlobeNewswire
Tickers
ASLN
ASLAN Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update
October 27, 2023
From
ASLAN PHARMACEUTICALS LIMITED
Via
GlobeNewswire
Tickers
ASLN
ASLAN Pharmaceuticals to Co-Host KOL Panel Discussion Today on Changes in the Clinical Trial and Treatment Landscape for Atopic Dermatitis
October 24, 2023
From
ASLAN PHARMACEUTICALS LIMITED
Via
GlobeNewswire
Tickers
ASLN
ASLAN Pharmaceuticals to Co-Host KOL Panel Discussion on Changes in the Clinical Trial and Treatment Landscape for Atopic Dermatitis
October 18, 2023
From
ASLAN PHARMACEUTICALS LIMITED
Via
GlobeNewswire
Tickers
ASLN
ASLAN Pharmaceuticals Presents New Data From Phase 2b Study of Eblasakimab in Atopic Dermatitis in Late Breaker Presentation at 32nd European Academy of Dermatology and Venereology Congress
October 13, 2023
From
ASLAN PHARMACEUTICALS LIMITED
Via
GlobeNewswire
Tickers
ASLN
ASLAN Pharmaceuticals Announces Acceptance of Late Breaker Abstract on Eblasakimab Phase 2b Results as Oral Presentation and Three Additional Abstracts at 32nd European Academy of Dermatology and Venereology Congress
September 22, 2023
From
ASLAN PHARMACEUTICALS LIMITED
Via
GlobeNewswire
Tickers
ASLN
ASLAN Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference
September 07, 2023
From
ASLAN PHARMACEUTICALS LIMITED
Via
GlobeNewswire
Tickers
ASLN
ASLAN Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update
August 11, 2023
From
ASLAN PHARMACEUTICALS LIMITED
Via
GlobeNewswire
Tickers
ASLN
Eblasakimab Monthly Dosing Shows Potential for Best-In-Class Therapy in Positive Phase 2b Study in Atopic Dermatitis
July 06, 2023
From
ASLAN PHARMACEUTICALS LIMITED
Via
GlobeNewswire
Tickers
ASLN
